Montag, 7. September 2015

Interview with Aligned AG

 


Switzerland has a long standing record of successful medical innovation and today hosts an increasing number of companies in the med tech industry, from small startups to global giants. However, rapid innovation in this industry is challenged by the continually evolving regulatory landscape.


We had the opportunity to talk to Anders Emmerich, the CEO of Aligned AG, about his view of the current innovation situation in Switzerland.




Mr. Emmerich, is rapid innovation in the med-tech industry an inherent impossibility?



Not at all. Just this year we have seen a virtual explosion of new health related products, centered around smartphones, wearables and apps and we have no reason to believe that it is going to slow down.


But I understand what you mean with your question. It is true that regulations, norms and standards put pressure on the development team since they require a level of documentation and documented proof rarely seen in other industries. As a matter of fact, our experience shows that up to 30% of the total device development effort is about documentation and none of the companies we have spoken to finds this to be reasonable. So if you experience the same, you are certainly not alone.


 



So what is wrong then?



Swiss manufacturing quality is excellent. The knowledge and expertise in the Swiss engineering workforce is also outstanding. However, sometimes all this excellence misses the target by not looking in the right direction.


It often strikes me that the level of optimization in device manufacturing and development is seldom matched in the documentation area. Surface coatings, manufacturing details and device driver sub-routines are getting analyzed into the smallest detail, but the documentation process is left largely unchecked. There is an enormous potential for savings and rationalizations to be made in this area.


 



Give us an example.



With an rising number of regulations and increasing complexity of the devices, the number of design control items to keep track of increases steeply.  The work-load of enforcing the corresponding documentation consistency increases exponentially. That requires tools and methods that can handle this level of documentation complexity.


Tools, like our ALM solution Aligned Elements, is there to handle all the day-to-day menial efforts, such as automatic version control, recording the audit trail, automatic calculations in risk assessments, lead you through approval processes and collecting signatures.


At the same time, our tool ruthlessly scan the documentation for inconsistencies and make them apparent well before the auditor lays his hands on your files. This will save a considerable amount of time, money and effort, freeing your engineers from menial documentation tasks and remarkably lower the risk of having to confront an auditor with a leaky technical file.


 



So documentation tools are the answer to the ever slowing innovation process?



No. A tool alone will never make the sufficient improvements. The success of a documentation tool like Aligned Element is heavily relying on Quality Management System in place. And this is a tricky one. Without a QMS you will never get to the market. But a cumbersome QMS can be a significant source of those 30% I talked about. It takes experience and knowledge to chisel out an efficient yet sufficient QMS.


 



But isn’t the additional requirements posed by regulatory risk management an important factor on increasing the documentation burden?



That depends. The risk perspective is there to make us build safe devices. It should ideally be an innovation driver. However, many manufacturers are so convinced that they already make excellent (and safe) devices that they fail to take regulations like ISO 14971 to heart. The risk management documentation then only becomes an necessary evil that subsequently does not receive the attention needed to make it efficient. So then you end up doing it wrong AND slow.


 


Companies also fail to see that risk management and design control management cannot be separated. And still manufactures insist in keeping risk management and design control management in separate systems! The traceability will invariable tie these two aspects together and the level of manual checks required to keep the data consistent will rise sharply. This is something we have been very careful to integrate in our solution.


 



What do you see in the future for Swiss medical device innovation?



I think that the documentation aspect of med-tech product development is going to get increased attention and that it will become an important competitive dimension in the industry. If you can outsmart your competitor and perform a more efficient documentation process, you will shorten your time-to-market at a lower cost.


 


About Aligned AG


Aligned AG provides Aligned Elements, an ALM system to ensure compliant


development documentation for regulated products in the Medical Device


Industry. For more information, visit www.aligned.ch or write us at info@aligned.ch.


 


#LabAutomation #medtec


 



Interview with Aligned AG

Samstag, 5. September 2015

After Work Networking (CH)




When: Every first tuesday of the month 17.00 h


Location: Momento Caffè & Lounge, Wagistrasse 12, 8952 Schlieren, www.wagi-s.ch


Who: Academic researchers, technicians, CEOs, scientists, sales managers ... everybody is invited to join us!


Event sponsors: Novartis International AG and Raiffeisenbank an der Limmat







TECHNOPARK® ACADEMY



Pracademic Workshops für innovative Jungunternehmer

Die TECHNOPARK® ACADEMY konzipiert und organisiert kompakte Workshops zur Förderung von innovations- und technologieorientierten Jungunternehmen im Wachstum, mit dem Ziel, Theorie- und Praxis zu verbinden, um einen konkreten Umsetzungsnutzen zu generieren.


Ausgewiesene Referenten aus Wirtschaft und Wissenschaft (Pracademics) garantieren einen praxisorientierten Wissenstransfer.


Attraktive Preise werden für innovative high-tech Jungunternehmen, die im TECHNOPARK®-, Science Park- und KTI Start-up-Verbund angegliedert sind, angeboten.


Weitere Infos und Anmeldung: www.tp-academy.ch




After Work Networking (CH)

Mittwoch, 26. August 2015

ELA 2015

ELA 2015 - Advances in LabAutomation & Robotics


 


SELECTBIO, the organisers of this track of the ELA 2015 conference programme are presenting a collection of speakers with experience in laboratory automation.  The three sessions are broadly divided into hardware, software and science.  In the hardware section, industrial suppliers from the areas of robotics, components and lab-on-a-chip will cover current and future trends in equipment supply for the lab automation business. For software we have thought leaders from control software, LIMS and the SiLA standards organisation.  Finally the science section will allow innovative thinkers from industry and academia to present new ideas.


 


Davies new


Anthony Davies

Director of Translational Cell Imaging, The Queensland University of Technology


Crook


Malcolm Crook

Director, Peak Analysis & Automation PAA Ltd


King


Ross King

Professor of Machine Intelligence,University of Manchester


 



Download PDFs:


ELA2015-Rooms


ELA2015-Hall-Position


 




ELA 2015

Freitag, 21. August 2015

Automation Leaders Siemens and Inpeco Extend Long-Term Partnership

Siemens Healthcare Diagnostics and Inpeco have signed a new contract that extends the companies’ long-lasting status as preferred partners in laboratory automation. Siemens and Inpeco will be working closely together to design and deliver complex, custom solutions to help our customers meet their business and clinical needs.


Siemens and Inpeco have been jointly pioneering in the field of laboratory automation since 1999. Siemens is the market leader in laboratory automation installations, with the largest installed base of total laboratory automation solutions in the world. Inpeco, a highly-respected innovator of laboratory automation products, has played a key role in that success. Siemens has successfully installed more than a thousand track-based total lab automation solutions, and the Siemens-Inpeco partnership is responsible for the majority of these, including the longest and most complex automation tracks ever built. The Siemens-Inpeco partnership combines the market-leading strengths of each company. “Siemens’ expertise in engineering, project management and workflow design together with Inpeco’s innovation power is a proven, winning combination,” said Franz Walt, CEO, Chemistry, Immunoassay, Automation and Diagnostics IT Business Unit, Diagnostics Division, Siemens Healthcare. “That’s why the world’s largest laboratories trust us to improve turnaround times, cut costs and reduce errors for improved patient outcomes.” “The strengths that we each bring to this partnership allow Siemens and Inpeco to consciously address the growing demand for advanced and innovative TLA solutions,” said Andrea Pedrazzini, President, Inpeco. “Laboratory medicine and healthcare require reliable and self-sufficient solutions capable of delivering seamless performance and full satisfaction to our customers and we work hard every day to reach these goals.” Together, Siemens and Inpeco share a proud 15-year tradition of excellence in laboratory automation.



As a result of this long term contract, the Siemens-Inpeco partnership will continue to transform diagnostic medicine with Lean total laboratory automation solutions that are scalable, flexible, reliable, multi-disciplinary, and enable connectivity to third party analyzers.



 


See more at: SelectScience



Automation Leaders Siemens and Inpeco Extend Long-Term Partnership

Montag, 10. August 2015

Benchmark technological developments and explore best practices in biomanufacturing

The Bio Pharmaceutical industry is making a capital investment of approximately $8 billion in new facilities in Ireland, most of which has come in the last 10 years, representing close to the biggest wave of investment in new BioTech facilities anywhere in the world.



Join us at BioProduction 2015 in Dublin this October to see why so much is being invested in this area and to network with leading players within this growing industry!




 


BioProduction 2015: Europe’s leading and largest event for a comprehensive update on all aspects of large scale biological manufacturing. Providing insights on the latest technologies, upstream/downstream processing, process analytics, the implementation of continuous manufacturing, facility design, flexibility facilities and single use systems to reduce inefficiencies during the bio manufacturing process.


4 Conferences – 1 Exhibition - 1 Congress


  • Conference 1: Continuous Manufacturing

  • Conference 2: Upstream Processing- Production, Development & Analytics

  • Conference 3: Manufacturing Strategy & Technology

  • Conference 4: Downstream Processing

 


250+ Industry Experts – 130+ Companies Represented – 10 Interactive Discussions


 


Global panel of senior level industry professionals companies including:



  • Sean McEwen, Vice President, Biologics Manufacturing, AbbVie Manufacturing Mgmt Ltd, Ireland


  • Guy McDonnell, Director of Engineering &EHS, Pfizer, Ireland


  • Trent Carrier, Vice President, Vaccine Technology & Engineering, Takeda Vaccines, USA


  • Roman Necina, Vice President Process Science & Technical Operations, Baxalta, Austria


  • Thilo Henckel, Vice President Manufacturing, Roche Diagnostics GmbH, Germany


  • Lada Laenen, Senior Director; Allston Landing Manufacturing Science and Technologies Head, Genzyme Corporation, USA


  • Lars Dreesmann, Executive Director, Head of Clinical Supply & Transfer, Biopharma Bioprocess & Pharmaceutical Development, Boehringer Ingelheim, Germany


  • Ciaran Brady, Director, Biotech Technical Services/ Manufacturing Sciences, Eli Lilly and Company, Ireland


  • Joe Runner, Manufacturing Technical Specialist, Genentech, USA


  • Weibing Ding, Principal Scientist, Process Development, Amgen Inc., USA

 


For more information on the 2015 event please visit the event website at www.bio-production.com



Benchmark technological developments and explore best practices in biomanufacturing

BioData World Congress 2015

Are you, like Barack Obama, trying to push the science of genomics to the next leveI - the development of precision medicines?


You will be in good company if you are. Leading healthcare institutes across the world are grappling with this thorny challenge and many have found some very innovative and exciting solutions. These initiatives will be showcased, discussed and debated at one of the most exciting and innovative events in the genomics calendar.




The BioData World Congress, held at the Wellcome Genome Campus this October will:



  • Use novel formats to address the challenges in getting the benefits of genomic science to the patient - including narrative drama, roundtables, site visits and TED style talks

  • examine the science and technology that is shaping and revolutionising our understanding of disease

  • review the game changing innovation, roadblocks and critical success factors in the utilisation of genomic data

  • identify how big data is driving developments in precision medicine

Ticket prices start at £350. Register now to receive the best possible rates


We have an amazing faculty, a veritable who’s who in genomics, headlined by Eric Green from NHGRI and supported by visionaries from across the globe including The Broad Institute, Google, Harvard Medical School, EMBL-EBI, Wellcome Trust Sanger Institute, and Genomics England.


Quote discount code XSJJ


For more information please visit event website


To download the brochure please click HERE



BioData World Congress 2015

Mittwoch, 5. August 2015

What is better than a Hamilton STARlet?

hamilton

Exactly, a Star Plus. Basically it is the same maschine, just 2 of those connected to each other.

As you can only mount one arm to a single Hamilton Star(let), this setup opens a whole new level of

possibilities. You can, for instance, have the first Starlet equiped with a multichannel arm which

prepares your samples on a MTP and than hand over the plate to the second maschine equiped with a

96-Head to perform the whole workup of your assay. Great, isn`t it!



So this is the benefit for the user, but why does Hamilton not just construct a larger maschine?

This a question has a few anserws:


- Hamilton dont have to invent new parts, but only a connector between the 2 Starlets

- There might be a stability problem for the whole maschine if you (just) enlarge parts

- Shipment and build up is more comfortable with smaller parts

- The user can seperate both Starlets if he/she decides to continue with different assays


 


Here you can see a pdf of a Hamilton STAR plus setup:


A_fully_automated_system_for_storage_of_compounds_and_assay_plate_production_from_compound_stocks



What is better than a Hamilton STARlet?